Rheumatoid Arthritis Treatment Guideline

First-Line Treatment Strategy

• The American College of Rheumatology recommends methotrexate as the first-line DMARD for most patients with rheumatoid arthritis, rapidly escalated to 20-25 mg weekly (or maximum tolerated dose), and combined with short-term low-dose glucocorticoids as bridging therapy 1, 2
• Methotrexate should be started at 7.5-10 mg weekly and rapidly escalated to 20-25 mg weekly within 4-6 weeks, as this represents the optimal therapeutic dose 4

Bridging Glucocorticoid Therapy

• Low-dose glucocorticoids (≤10 mg/day prednisone equivalent) should be added when starting DMARDs in patients with moderate or high disease activity 5, 3
• Glucocorticoid duration should be limited to less than 3 months and tapered as rapidly as clinically feasible to minimize long-term adverse effects including cataracts, osteoporosis, and cardiovascular disease 6, 5, 3

Treat-to-Target Approach

• Disease activity should be monitored every 1-3 months using validated measures (SDAI, CDAI, or DAS28) and escalate therapy if the treatment target is not achieved within 3-6 months 1, 2, 3
• The treatment target should be remission or low disease activity 6, 5, 3

Treatment Escalation Algorithm

• If methotrexate monotherapy fails after 3 months in patients with moderate-to-high disease activity, add a biologic DMARD (preferably a TNF inhibitor) or targeted synthetic DMARD in combination with methotrexate 1, 6, 3
• TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) are the preferred first biologic agents 3, 4

Special Populations

• For patients with heart failure (NYHA class III or IV), non-TNF inhibitor biologics or targeted synthetic DMARDs should be used instead of TNF inhibitors, as TNF inhibitors can worsen heart failure 1, 4
• For patients with hepatitis B infection, prophylactic antiviral therapy is strongly recommended for those initiating rituximab who are hepatitis B core antibody positive, regardless of surface antigen status 1

Monitoring Requirements

• Tuberculosis screening (TST or IGRA) should be performed before initiating biologics or JAK inhibitors 7, 3
• Hepatitis B and C screening should be performed before initiating biologics 7, 3

Treatment Tapering

• For patients in sustained remission (at least 6 months of low disease activity or remission), consider cautious de-escalation of therapy through shared decision-making 8, 3
• Approximately 15-25% of patients may achieve sustained drug-free remission, particularly those with shorter symptom duration, absence of rheumatoid factor or anti-CCP antibodies, lower disease activity before remission, and less baseline disability 3